Varex (VREX) Form 4: Director reduces stake to 19,477 shares

Rhea-AI Filing Summary

Jay K. Kunkel, a director of Varex Imaging Corp (VREX), sold 3,000 shares of the company's common stock on 08/14/2025 at $10.49 per share. After the sale, he beneficially owned 19,477 shares, reported as direct ownership. The Form 4 disclosure records the transaction and the sale price for each share.

The filing provides a straightforward record of insider liquidity: a director reduced his stake by 3,000 shares while maintaining a mid-sized direct holding in the company. No options, derivative transactions, or other compensatory arrangements are reported.

Positive

• Transparent disclosure: The director reported the sale on Form 4, providing clear detail on shares sold, price, and remaining direct ownership.
• No derivatives reported: The filing shows only a straightforward sale of common stock with no associated options or complex instruments.

Negative

• Director share sale: A director disposed of 3,000 shares, which may be viewed negatively by some investors interpreting insider selling as reduced confidence.

Insights

Financial Analyst

TL;DR: A director sold a small block of shares, reducing direct holdings to 19,477; transaction appears routine rather than strategically material.

The sale of 3,000 shares at $10.49 reduces the reporting person’s direct stake but does not indicate derivative exercises or other compensatory transactions. Relative to the post-sale holding, the disposition represents a modest liquidity event. For investors, this disclosure is useful for transparency but does not on its own signify a change in company fundamentals.

Corporate Governance Expert

TL;DR: Director sale disclosed on Form 4 shows governance transparency; size and nature of sale suggest routine personal trading.

The Form 4 shows the reporting person acted within reporting rules and disclosed direct ownership after the sale. There is no indication of insider trading plan usage or related-party transactions disclosed in this document. From a governance perspective, prompt public disclosure preserves compliance and market transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunkel Jay K.

(Last) (First) (Middle)

C/O VAREX IMAGING CORP

1678 S. PIONEER ROAD

(Street)

SALT LAKE CITY UT 84104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Varex Imaging Corp [ VREX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		S		3,000	D	$10.49(1)	19,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All individual shares were sold at a price of $10.49

Remarks:

	/s/ Jay K. Kunkel	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did VREX report for Jay K. Kunkel?

The Form 4 reports that Jay K. Kunkel sold 3,000 shares of Varex Imaging common stock at $10.49 per share on 08/14/2025.

How many VREX shares does the reporting director own after the transaction?

After the reported sale, the director beneficially owned 19,477 shares of Varex Imaging common stock.

Was the transaction an option exercise or a derivative trade?

No. The filing shows a non-derivative sale of common stock only; Table II lists no derivative transactions.

Does the Form 4 indicate the sale was part of a 10b5-1 trading plan?

The document does not indicate that the transaction was executed pursuant to a 10b5-1 plan; no plan notation is provided.

Who filed the Form 4 for VREX?

The reporting person identified is Jay K. Kunkel, who is listed as a director of Varex Imaging Corp.